Can three common drugs boost chemotherapy against pancreatic cancer?

NCT ID NCT06030622

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This pilot trial is testing whether adding a combination of three widely used drugs—metformin, digoxin, and simvastatin (called C3)—to standard chemotherapy (gemcitabine) can safely help people with advanced pancreatic cancer that has not responded to prior treatment. The study will enroll about 25 adults with metastatic pancreatic cancer. Participants will receive C3 along with gemcitabine for up to two years, or C3 alone if they decline chemotherapy. The main goals are to assess safety and tolerability, and to see if the combination can reduce tumor burden or prolong life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of three common drugs—metformin, digoxin, and simvastatin (called C3)—given with or without the chemotherapy gemcitabine.
What this could lead to
If this approach works, it could offer a new, relatively inexpensive treatment option for advanced pancreatic cancer, potentially slowing tumor growth and extending survival.
What could go wrong
This is an early, small pilot study, so results may not be conclusive. The combination may cause side effects or may not be more effective than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SUNY Downstate Health Sciences University

    RECRUITING

    Brooklyn, New York, 11203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.